search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Bayesian optimized Propofol Target-Controlled Infusion


- candidate number17499
- NTR NumberNTR4518
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR16-apr-2014
- Secondary IDsMETc 2013/374 
- Public TitleBayesian optimized Propofol Target-Controlled Infusion
- Scientific TitleBayesian optimized Propofol Target-Controlled Infusion
- ACRONYMBOP-TCI-1
- hypothesisWe hypothesize that adaptation or tuning of the population PKPD model of propofol will decrease the residual error between predicted and measured plasma-concentrations during maintenance of anaesthesia. The adapted PKPD models can also be used online to calculate propofol infusion rates required for the target concentrations set by the responsible anaesthetist. Doses given to the patients remain within the control of the attending anaesthetist at all times and within clinically accepted dosing guidelines. We only test whether the error between prediction and measurement decreases when an individualized PKPD model is used to predict required propofol infusion rates compared to a non-adaptive population typical value PKPD model.
- Healt Condition(s) or Problem(s) studiedPropofol
- Inclusion criteria-Age between : 18 years and 75 years
-Informed patient consent
-ASA Class (American Society of Anesthesiologists physical status) I- III
- Scheduled for elective surgery under general anaesthesia with propofol and requiring an arterial line for invasive blood pressure monitoring as part of their clinical care will be enrolled.
- Exclusion criteria•patient refusal
•CNS diseases (dementia, CVI, seizures, psychiatric diseases)
•Regular intake of CNS active drugs (benzodiazepines, antidepressants, antipsychotics, anticonvulsants)
•Regular intake of opioids (morphine > 30 mg/day)
•Relevant hepatic disease (Child B or higher)
•Body mass index (BMI) <18 or >35 kg/m2
•Pregnancy, or currently nursing
•Overt signs of alcohol abuse
•Contraindications or allergies to the drugs used in the study
•Expected blood loss during surgery > 2000 ml
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingSingle
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-mei-2014
- planned closingdate1-mei-2015
- Target number of participants120
- InterventionsPatients receive propofol by means of a PKPD model. Initially a classical population based PKPD model is used. Based on results from intra-operative sampling an individualized PKPD model is used. Anesthesiologists will know when changes in regimen can occur. However, due to blinding, they will not know whether the patient is enrolled in the control group (nothing changes) or in the intervention group (regimen is individualized).
- Primary outcomeWe hypothesize that online adaptation or individualization of the population PKPD model of propofol will decrease the residual error between predicted and measured plasma-concentrations during maintenance of anaesthesia, when the adapted PKPD models are used to calculate propofol infusion rates required for the plasma concentrations set by the responsible anaesthetist
- Secondary outcomeSecondly, we will compare the hypnotic and haemodynamic stability before and after the adaptation as measured by EEG and other vital signs clinical monitoring
- Timepoints1 day = the day of the operation
- Trial web site
- statusplanned
- CONTACT FOR PUBLIC QUERIES R. Spanjersberg
- CONTACT for SCIENTIFIC QUERIESProf. dr. M.M.R.F. Struys
- Sponsor/Initiator University Medical Center Groningen (UMCG)
- Funding
(Source(s) of Monetary or Material Support)
University Medical Center Groningen (UMCG)
- Publications
- Brief summaryPopulation based pharmacokinetic-dynamic (PKPD) models of propofol are used in daily practice to titrate propofol towards a predicted plasmaand/ or effect-site concentration. 1-4 It has been accepted that the population based prediction of the propofol plasma concentration may have an error of about 20% compared to the measured propofol concentrations in the individual patient. 5 This error is considered acceptable in the clinically applied new generation target controlled infusion (TCI) systems for propofol administration 6-8.
Recently, new technology has been developed to measure propofol concentrations in plasma with minimal delay of about 10 minutes after sampling. This technology opens opportunities to decrease the residual error between predicted (population) and measured (individual) propofol plasma concentrations during maintenance of anaesthesia. A decrease of the prediction error has several potential advantages such as less accumulation of drug, faster recovery from anaesthesia, less overshoot in propofol effect when adjusting the dose etc…
Our study tests whether online adaptation of the population PKPD model (being used to calculate the infusion rates during maintenance of anaesthesia), based on differences measured and predicted concentrations, will decrease the residual errors between subsequent measurements and predicted concentrations. Such an individualization of the population PKPD should be done in a Bayesian approach as it has been shown to be a good method of updating pharmacokinetic models during infusion, when intermittent drug concentration measurements are performed 9. This method adapts the starting (population) pharmacokinetic model, on the basis of the measured blood samples to generate a patient-individualized model.
- Main changes (audit trail)
- RECORD16-apr-2014 - 13-mei-2014


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl